Timothy Hung-Po Chen

Timothy Hung-Po Chen

Auto-generated profile, based on publicly available information

Timothy Hung-Po Chen

Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2026 in Cancer Research
Verified
Journal Article
Open access
ABAshenafi Bulle
Ashenafi Bulle
YCYali Chen
Yali Chen
HLHuaping Li
Huaping Li
TCTimothy Hung-Po Chen
Timothy Hung-Po Chen
IKIftikhar Ali Khawar
Iftikhar Ali Khawar
KLKian-Huat Lim
Kian-Huat Lim
Acquired resistance limits the therapeutic efficacy of KRAS-MAPK inhibitors in pancreatic ductal adenocarcinoma (PDAC). As transcriptional plasticity and epithelial-to-mesenchymal transition (EMT) have been implicated in resistance, we sought to study the molecular mechanisms driving these changes to uncover actionable vulnerabilities. Sustained KRAS-MAPK inhibition induced interferon (IFN) and NF-κB signaling and promoted cell state change mimicking an EMT state associated with drug resistance. Network analysis identified the IFN-inducible E3 ubiquitin ligase TRIM22 as a central regulator of this response. Mechanistically, TRIM22 promoted proteasomal degradation of IκBα, resulting in sustained NF-κB and EMT program activation that coincided with a basal-like transcriptional cell state. TRIM22 expression was driven by IRF1 and IRF9 following relief of ERK-mediated transcriptional repression during pathway inhibition. EMT induction was accompanied by marked upregulation of TROP2 (TACSTD2), an NF-κB target gene enriched in basal-like PDAC cell states. Combining TROP2-directed antibody–drug conjugate sacituzumab govitecan with KRAS or ERK inhibitors significantly suppressed PDAC tumor growth in xenograft models. Overall, prolonged KRAS-MAPK inhibition activates an IFN–TRIM22–NF-κB axis that drives EMT and therapeutic resistance in PDAC, while revealing TROP2 as a clinically actionable vulnerability to overcome acquired resistance. Significance: TRIM22 drives interferon-induced EMT and NF-κB–dependent TROP2 upregulation to drive resistance to KRAS-MAPK inhibition in pancreatic cancer, which can be overcome by combining sacituzumab govitecan with KRAS-MAPK inhibitors.